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Alzheimer’s disease is a complex condition which manifests within the brain causing 
loss of brain function and resultant cognitive decline. The retina is closely related to 
the brain and it has been proposed that the retina may be adversely affected in 
Alzheimer’s disease (AD). If AD-associated pathologies can be detected in the retina 
and they correlate with brain pathology, this has the potential to solve clinical 
problems regarding the diagnosis and monitoring of AD. Recent research has shown 
that amyloid beta (Aβ); the protein responsible for cerebral amyloid plaques in AD 
may also accumulate within the retina in those affected by the condition. My research 
involved the application of immunohistochemistry techniques to identify Aβ within the 
retina of AD individuals and transgenic mouse models of AD, and to explore if an 
association exists between Aβ and retinal vasculature. Aβ accumulations were 
identified in flat-mount retina and cross-sections from AD and age-matched control 
eyes. Aβ labelling was found in clusters associated with retinal blood vessels, in 
spherical structures within drusen, choroid and sclera and an intracellular labelling 
was detected in the inner layers of the human retina. Where Aβ accumulations were 
detected extracellularly in the human retina, these were in few areas. No increase in 
Aβ accumulations was seen in the retina of AD samples when compared to age-
matched controls. No Aβ accumulations were found in the retinas of transgenic mouse 
models of AD but an intracellular labelling was detected in the inner retina, similar to 
findings in human tissue. Based on these findings, it is not possible to conclude that 
retinal Aβ deposits have the potential to reflect the hallmark cerebral Aβ plaques 
which contribute to the progression of AD. Given the challenges associated with the 
diagnosis and treatment of AD, the concept of abnormal retinal Aβ accumulation as a 
potential pathology of AD should not be overlooked until further in-depth research has 











Alzheimer’s disease (AD) is a progressive, neurodegenerative condition which 
primarily affects the brain and can lead to severe cognitive impairment. It is the most 
common subtype of dementia affecting approximately 46.8 million people worldwide 
(Prince et al., 2016). Dementia is the set of symptoms resulting from cognitive decline 
such as language and behavioural problems, memory loss and confusion. With 
progression of AD, the symptoms worsen and begin to interfere with daily life. At 
present, the pathogenesis of AD is not coherently understood therefore no curative 
therapies for the condition have been developed.  
Alzheimer’s Disease – Amyloid beta and Tau 
 AD is characterised by neurodegeneration within the brain. The 
neurodegenerative process is thought to involve neuronal loss (Yankner et al., 1996; 
Padurariu et al., 2012), synaptic changes (Selkoe, 2002; Scheff et al., 2006), 
inflammatory mechanisms (Akiyama et al., 2000; Frautschy et al., 1998) and oxidative 
stress (Christen, 2000; Manczak et al., 2006). This vast cerebral degeneration results 
in shrinkage of the brain when compared to that of a healthy individual (Double et al., 
1996). Although the exact pathogenesis of the condition is not clearly defined, it has 
been linked to abnormal accumulations of misfolded proteins within the brain. The two 
main proteins associated with AD are amyloid beta (Aβ) and tau. Aβ and tau are 
present in the healthy brain; however, are abnormally processed and accumulate in 
AD leading to the hallmark brain pathologies; senile plaques consisting of Aβ (Masters 
et al., 1985) and neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau 
(Grundke-Iqbal et al., 1986) (Figure 1). The mechanisms in which these two abnormal 
protein accumulations lead to neurodegeneration remain incompletely understood. 
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Figure 1. Alzheimer’s Disease. Extracellular amyloid plaques and intracellular neurofibrillary tangles of 
tau protein are thought to induce cerebral tissue damage and result in shrinkage of the brain (A.D.A.M, 
2017).  
 
 Cerebral plaques consisting of Aβ are one of the two hallmark lesions 
described in AD. The formation of these extracellular plaques involves processing of 
the membrane-bound amyloid precursor protein (APP) (Figure 2). APP can be 
processed via two pathways; amyloidogenic and non-amyloidogenic. The 
amyloidogenic pathway results in the formation of Aβ peptides. In this pathway, APP 
is sequentially cleaved by β-secretase to generate sAPPβ and C99 fragments. C99 
is then cleaved by γ-secretase to generate Aβ peptides. This cleavage by γ-secretase 
can generate Aβ peptides of various lengths, of which 40 amino acids (Aβ40) and 42 
amino acids (Aβ42) are the most frequently formed (Selkoe, 2001). APP can also be 
processed via the non-amyloidogenic pathway which does not generate Aβ peptides. 
In this case, APP cleavage by α-secretase results in the fragments sAPPα and C83. 
C83 can then be cleaved by γ-secretase to form AICD and p3 fragments.  
 
Figure 2. Processing of amyloid precursor protein (APP) and amyloid plaque formation. (A) APP 
can be processed via amyloidogenic or non-amyloidogenic pathways. Amyloidogenic involves APP 
cleavage by β-secretase to form sAPPβ and C99. Membrane bound C99 is then cleaved by γ-secretase 
to form Aβ peptides which can aggregate into Aβ plaques. Non-amyloidogenic processing involves 
sequential cleavage by α-secretase and γ-secretase to generate p3 and AICD fragments. No Aβ peptides 




The most frequently formed Aβ peptides are Aβ40 and Aβ42. The longer 
peptide Aβ42 is more prone to aggregation and is overproduced in individuals which 
suffer from AD. Aβ42 is the most abundant form in cerebral plaques; however, Aβ40 
can also be aggregated (Hardy & Selkoe, 2002).  
 NFTs consisting of hyperphosphorylated tau are another neuropathology 
characterised in the AD brain. Tau is a protein which facilitates microtubule stability 
within cells. It can become increasingly phosphorylated by kinases, 
hyperphosphorylated tau aggregates together and is sequestered into intracellular 
NFTs (Figure 3). This leaves less tau available for microtubule stability leading to 
degeneration of neuronal cells (Selkoe, 2001).   
 
Figure 3. Formation of neurofibrillary tangles (NFTs) of hyperphosphorylated tau. (A) Microtubule 
(MT)-associated protein tau is phosphorylated by kinases. Hyperphosphorylated tau aggregates to form 
soluble aggregates which are deposited into NFTs. (B) NFTs within the brain (Götz & Ittner, 2008; 
Serrano-Pozo et al., 2011). 
 
Amyloid and Vascular Hypotheses for AD 
The exact initiating events responsible for the formation of Aβ plaques and 
NFTs and therefore the onset of AD are incompletely understood. One hypothesis 
which has been extensively studied is the amyloid cascade hypothesis (Hardy & 
Higgins, 1992). It suggests that the deposition of Aβ into extracellular senile plaques 
is the initiating event in the pathogenesis of AD and the presence of these plaques 





(Hardy & Higgins, 1992; Götz et al., 2001). All the other characteristics that 
accompany AD such as inflammation, vascular dysfunction and neuronal damage are 
also thought to result from these cerebral plaques (Hardy & Higgins, 1992). The 
overproduction of Aβ peptides which leads to their deposition is thought to be due to 
a disruption in the mechanisms responsible for production and clearance of the 
peptides (Hardy & Selkoe, 2002). However, it is unknown whether the 
neurodegenerative process relies on the formation of senile plaques or whether 
individual Aβ peptides can cause the neuronal damage associated with AD (Selkoe, 
2001). 
More recently a vascular hypothesis for AD onset has been explored (De La 
Torre, 2002; De La Torre, 2004). This hypothesis suggests that neurovascular 
dysfunction may be responsible for initiating AD. Cerebral vascular dysfunction can 
lead to a lack of brain perfusion and hence hypoxia. Consequently, neurones within 
the brain would not be adequately supplied with blood and neuronal cell death would 
occur (Zlokovic, 2011). This vascular-associated damage may induce the 
overexpression and aggregation of Aβ peptides and their deposition into cerebral 
plaques (Koike et al., 2010; Garcia-Alloza et al., 2011). Further evidence which 
proposes that AD may have a vascular disease component includes vascular risk 
factors such as diabetes mellitus, hypertension, heart disease and smoking which are 
associated with a reduction of cerebral perfusion and have been found to increase 
the risk of AD (Luchsinger et al., 2005). In addition, one of the key AD proteins has 
been found to be associated with cerebral vasculature. Cerebral amyloid angiopathy 
is a condition in which Aβ is deposited in the walls of cerebral blood vessels. This 
process may narrow blood vessels and hence affect cerebral blood supply. The 
condition is commonly found in AD and may contribute to its pathogenesis (Thal et 
al., 2008). Furthermore, dementia due to a lack of cerebral blood supply is clinically 
diagnosed as vascular dementia. Vascular dysfunction can co-exist with AD-
associated pathologies (cerebral Aβ plaques and NFTs) which is termed mixed 
dementia. Therefore, an overlap exists between vascular dementia and AD which 
further supports that AD has a vascular basis (Iadecola, 2010). AD is a complex 
condition in which the exact causal mechanisms are not well established; however, 
collectively this evidence would strongly suggest that vascular involvement 





Clinical Challenges in the Diagnosis and Monitoring of AD 
The uncertainty surrounding the mechanisms responsible for AD onset and 
progression has led to a number of clinical challenges (Tarawneh & Holtzman, 2012). 
Difficulties have arisen in the diagnosis and monitoring of the condition. Making an 
early diagnosis of AD is almost impossible as a definitive diagnosis can only be 
established by identification of cerebral Aβ plaques and NFTs during post-mortem 
examination of the brain. Individuals can be diagnosed with possible or probable AD 
based on their clinical symptoms; however, this will not be confirmed until after death 
(McKhann et al., 2011). Current methods for diagnosis and monitoring include brain 
imaging scans such as positron emission tomography (PET), computed tomography 
(CT) and magnetic resonance imaging (MRI). Although brain scans are not ideal as 
they are expensive, not widely available to the vast amount of suspected AD sufferers 
and unable to diagnose the condition with complete certainty (Johnson et al., 2012). 
Cerebral spinal fluid (Ferreira et al., 2014) or blood samples (Koyama et al., 2012) 
may be analysed in an attempt to locate biomarkers such as Aβ or phosphorylated 
tau (ptau); however, this involves invasive procedures and results are not reliable 
enough to be used in routine diagnosis of AD. Furthermore, a major concern is that 
current diagnostic methods focus mainly on the elimination of other conditions and 
none are reliable enough to diagnose AD with complete certainty. A highly specific & 
sensitive diagnostic method for AD has yet to be established. As well as these, the 
abnormal protein accumulations of Aβ plaques and NFTs in the brain have been 
described to manifest years before symptoms of cognitive decline appear in sufferers 
(Price et al., 2009). This makes it impossible to make an early diagnosis in the 
presymptomatic stages of AD. Methods which can identify AD-associated pathologies 
early in the disease progression are urgently needed. First, a better understanding of 
the pathogenesis of the condition is required in order to provide patients with a more 
accurate and earlier diagnosis. Cerebral plaques and NFTs which present within the 
brain in AD makes them ideal targets for AD diagnosis; however, effective strategies 
to locate these early in disease progression have not yet been developed. The 
condition currently has no curative therapies and treatment options available can only 
alleviate the symptoms and slow the progression of AD. A greater understanding of 
the disease mechanisms needs to be established to allow an earlier detection and 





Could Retinal Pathology Represent Brain Pathology in AD? 
AD is a condition which predominantly affects the brain. The eye has been described 
as the ‘window to the brain’ and recent research has proposed that the retina may too 
be adversely affected in AD (Lim et al., 2016; Javaid et al., 2016). The retina is a light-
sensitive tissue located at the back of the eye. Its function is to convert light rays into 
neural signals which are relayed to the brain via the optic nerve. The retina is directly 
linked to the brain, both are part of the central nervous system and have common 
embryonic origin, evolving from the neural crest (Etchevers et al., 2001). Given that 
the retina is a developmental outgrowth of the brain, it is not surprising that AD 
pathologies may develop in the eye. As a result, the identification of AD-associated 
changes within the retina is a growing area of research. Retinal abnormalities which 
may be associated with AD include the degeneration of retinal ganglion cells (Blanks 
et al., 1996), nerve fibre layer thinning (Berisha et al., 2007), optic nerve degeneration 
(La Morgia et al., 2016), reductions in blood flow (Berisha et al., 2007), vasculature 
changes (Frost et al., 2013; Williams et al. 2015), Aβ and ptau accumulation (Koronyo-
Hamaoui et al., 2011; La Morgia et al., 2016; Koronyo et al., 2017; Schön et al., 2012) 
and inflammation (Liu et al., 2009). The retina is a tissue which can be easily 
accessed, viewed non-invasively and inexpensively making it an ideal target for in 
vivo imaging of AD. If retinal pathology is representative of brain pathology in AD, 
investigation of the retina could potentially provide an answer to the clinical problems 
regarding the condition. 
 
Figure 4. Structure of the retina. Retinal layers can be seen in the diagram (left) and confocal 
microscopic image (right). NFL-nerve fiber layer, GCL-ganglion cell layer, IPL-inner plexiform layer, INL-
inner nuclear layer, OPL-outer plexiform layer, ONL-outer nuclear layer, PL-photoreceptor layer, RPE-
retinal pigment epithelium, BM-Bruch’s membrane and C-choroid (The Retina Reference, 2017). 
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Evidence of Retinal Aβ Deposits in AD 
The presence of abnormal accumulations of Aβ in the AD retina remains 
controversial. My research has focused mainly on the identification of Aβ deposition 
within the AD retina by immunohistochemistry techniques. Research in animal models 
of AD has produced promising results; however, few experimental studies have 
successfully managed to identify Aβ deposits within the retina in human AD patients. 
The main research studies investigating Aβ deposition within the retina of human and 
animal and the methods used will be briefly described. 
Firstly in terms of human retinal Aβ deposition, a key experimental study of 
interest conducted by Koronyo-Hamaoui et al. (2011) claimed to identify Aβ plaques 
within the retina of human post-mortem eyes using a variety of different anti-Aβ 
antibodies as well as curcumin, a dye which binds to Aβ. They analysed 8 definite AD 
and 5 possible/probable AD retinas. Plaques were mainly found in the inner layers of 
the retina and different plaque morphologies were identified. A study by La Morgia et 
al. (2016) which included some of the same investigators as the previous study, 
managed to identify retinal Aβ plaques when investigating 5 post-mortem AD patient’s 
eyes using anti-Aβ monoclonal antibodies. They also detected an Aβ plaque in a 
healthy control retina. Similarly, a small study detected Aβ plaque-like structures in 
whole-mount retinas from 2 AD sufferers using the anti-Aβ antibody 6E10, the location 
within the retina was not specified (Tsai et al., 2014). Use of the 6E10 antibody will 
be highlighted in various studies as this is the anti-Aβ antibody predominantly used 
for the detection of Aβ in my research. A recent study conducted by Koronyo et al. 
(2017) which again included some of the same investigators as the initial study 
described, detected Aβ deposits within the retinas of 23 AD post-mortem eyes. An 
increase in retinal Aβ deposits were found in AD samples when compared to healthy 
age-matched controls. Retinal deposits were mainly found in the inner retinal layers 
and correlated with brain pathology of both AD and age-matched control samples. 
Classical, compact and diffuse plaques were identified and showed similar 
morphology but were smaller in size than cerebral plaques. Samples were analysed 
using a variety of antibodies specific to different regions of the Aβ peptide including 
the 6E10 antibody, and dyes which label Aβ. A loss of neuronal cells was also 
apparent in AD retinas when compared to healthy age-matched controls. Following 
on from in vivo imaging in live transgenic mice in a previous study (Koronyo-Hamaoui 
et al., 2011), the present study demonstrated in vivo detection of Aβ deposits in 10 
live AD patients. Patients were administered with curcumin and retinas were 
visualised with a scanning laser ophthalmoscope. Numerous individual plaques and 
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clusters of Aβ deposits were identified in the retinas of AD patient’s whist sparse 
deposits were located in age-matched controls. 
Conversely, some researchers report a lack of Aβ deposition in the retina of 
AD patients. Schön et al. (2012) failed to detect any Aβ plaques when investigating 6 
human AD post-mortem retinas using an anti-Aβ monoclonal antibody. Another study 
reported similar findings, failing to detect Aβ plaques in the 11 human AD post-mortem 
retinas analysed with an anti-Aβ monoclonal antibody and concluded that Aβ does 
not accumulate in the retina in an analogous state to within the brain (Ho et al., 2014).  
Aside from the retina, Aβ has been detected in other areas of the human eye. 
Goldstein et al. (2003) managed to detect Aβ40 & Aβ42 in the lens of non-AD and AD 
eyes and Aβ40 in aqueous humour of non-AD eyes. A variety of different techniques 
were used which included immunohistochemistry, mass spectrometry, western blot, 
and slit-lamp stereophotomicroscopy. They concluded that concentrations of Aβ in 
the lens and aqueous humour were comparable to those within the AD brain and 
cerebral spinal fluid respectively. Aggregates of Aβ have been detected in sub-retinal 
pigment epithelium (sub-RPE) structures known as drusen. Drusen are extracellular 
deposits which are located between the Bruch’s membrane and RPE. They can occur 
normally throughout the aging process (Löffler et al., 1995) but are also a pathogenic 
characteristic of age-related macular degeneration (AMD) (Anderson et al., 2004). 
Drusen are known to contain a diverse array of components such as Aβ, 
hydroxyapatite (HAP) and inflammatory and complement components (Anderson et 
al., 2004; Thompson et al., 2015;  Mullins et al., 2000; Johnson et al., 2000). Aβ 
peptides aggregate within drusen and present in a spherical form (Anderson et al., 
2004; Johnson et al., 2002). The ability for Aβ to spontaneously aggregate within 
drusen and AD-associated cerebral plaques may suggest similarities between drusen 
deposition and AD (Ritchie et al., 2011).   
With the difficulties associated with human tissue in research, animal models 
are being increasingly used to investigate AD. Transgenic animal models of AD focus 
mainly on the amyloid hypothesis and replicate elevated levels of Aβ by 
overexpressing APP and presenilins; which are members of the γ-secretase complex. 
This elevated level of Aβ results in its deposition into cerebral Aβ plaques which are 
characteristic in the AD brain. Research into whether Aβ accumulates in the retina of 
transgenic animal models of AD has resulted in more conclusive findings than 
research into human retinal tissue. Aβ plaques have been identified in the retina of 
animal models of AD by various experimental studies. The same study as previously 
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mentioned by Koronyo-Hamaoui et al. (2011) investigated the APPswe/PS1ΔE9 mouse 
model of AD which has mutations in APP and presenilin-1 (PS1); as well as the human 
AD retina. They detected retinal Aβ plaques in the mouse model of AD which were 
co-labelled with curcumin and a variety of anti-Aβ antibodies. Plaques were detected 
in almost all layers of the retina including NFL, GCL, IPL, INL, OPL, ONL and in the 
sclera of the transgenic mice eyes. Retinal plaques were detected in mice as young 
as 2.5 months old and when comparing retinal and cerebral pathology, retinal plaques 
occurred prior to those within the brain and increased with age and disease 
progression. As previously mentioned, they also managed to image retinal Aβ plaques 
in vivo in live transgenic mice using curcumin. Perez et al. (2009) detected retinal Aβ 
deposits in the same mouse model of AD (APPswe/PS1ΔE9) using anti-Aβ antibodies 
and thioflavin-S; a dye which stains fibrillar amyloid. Mice were aged 12-19 months 
and majority of plaques were found in the IPL and OPL of the retina. The plaques 
increased in number and size as the mice aged. They concluded that retinal plaques 
were similar in structure to those located within the brain of the same mice suggesting 
that retinal pathology correlates with brain pathology in AD. Consistent with these 
findings were results from another study investigating the same transgenic mouse 
model of AD. Mice of age 13-16 months were subjected to anti-Aβ antibodies and 
thioflavin-S staining. An increase in Aβ deposition was evident, as well as a number 
of other degenerative changes in the retina when transgenic mice were compared to 
wildtype mice. These included a loss of neurones in the GCL, thinning of the IPL and 
a reduction in the axons of the optic nerve (Gupta et al., 2016). The presence of Aβ 
deposits was detected in the NFL and GCL of the retina and within retinal and 
choroidal vasculature in another research study which investigated two different 
APP/PS1 mouse models of AD using an anti-Aβ antibody. Transgenic mice were aged 
between 7-27 months and an increase in Aβ load was apparent when comparing mice 
of age 7 months and 27 months. This study also detected a loss of neuronal cells 
within the GCL of retinas from transgenic mice which is characteristic of the 
neurodegeneration present in AD (Ning et al., 2008). Another study investigating 
transgenic mouse models of AD, found Aβ deposits in 14 month old Tg2576 mice. Aβ 
deposits were located in the neural retinal layers from GCL to ONL using anti-Aβ 
antibodies including the 6E10 antibody. Retinal thickness was decreased in 
transgenic mice, showing loss of cells within the retina (Liu et al., 2009). A possible 
Aβ labelling was detected in the GCL, INL, lens and cornea in an analysis of two 
mouse models of AD (Tg2576 and APPswe/PS1ΔE9) using anti-Aβ antibodies (Dutescu 
et al., 2009). Finally, Tsai et al. (2014) found Aβ plaque-like structures in the retina of 
eyes from a transgenic rat model of AD. These were located in the IPL, OPL & choroid 
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using the 6E10 antibody. A number of different pathologies related to AD have been 
identified in transgenic animal models. Transgenic animals are useful in research to 
model different aspects of AD; however, it must be acknowledged that they are not 
completely representative of how this complex and progressive disease would 
manifest in humans. 
Similar AD-associated pathologies have been detected in the retina of both 
human AD patients and transgenic animal models of AD. These include Aβ 
deposition, loss of neurones, thinning of retinal layers and degeneration of the optic 
nerve. If pathogenic changes characteristic of AD can be identified successfully in the 
retina and they are representative of brain pathology, the retina would provide an ideal 
target for diagnosis and monitoring of AD. Aβ accumulation has been described as 
the initiating event in AD pathogenesis (Hardy and Higgins, 1992), therefore much 
interest has been paid to its identification within the retina. My research has focused 
mainly on Aβ deposition within the retina of humans and transgenic mouse models of 
AD. In the interest of the vascular hypothesis for AD onset (De La Torre, 2002; De La 
Torre, 2004), I visualised the retinal vasculature to investigate if a relationship exists 



















Aims & Purpose of the Research 
AD is a complex, neurodegenerative condition which results in degeneration of the 
brain. Its pathogenesis is poorly understood. As a result, numerous clinical challenges 
have arisen in the diagnosis and monitoring of the condition. Novel methods which 
can detect AD-associated pathologies in the presymptomatic stage of the disease are 
urgently needed to aid an earlier diagnosis. It has been proposed that retinal 
pathology may represent brain pathology given the direct link between the two 
structures (Lim et al., 2016). The eye has advantages over the brain as it can be easily 
assessed, imaged non-invasively and inexpensively. Therefore detection of abnormal 
protein deposits associated with AD such as Aβ within the retina of the eye could be 
a potential answer to the clinical challenges which result from the condition. 
The aims of my research were: 
1. To identify Aβ within the retina of AD patients and transgenic mouse models 
of AD 
2. To investigate the relationship between Aβ and the retinal vasculature 
To investigate these factors I analysed the retinas from eyes of human AD patients 
and age-matched controls and from transgenic mouse models of AD and their 
wildtype littermates by immunohistochemistry techniques in order to identify Aβ 
















My project included research on retinal tissue from human and transgenic mouse 
models of AD. I aimed to investigate Aβ accumulation within the retina and how it was 
related to retinal vasculature.  
Initially I began my research on human tissue; first optimisation of the vascular 
labelling was carried out on non-AD samples. I then moved on to explore the detection 
of retinal Aβ in both non-AD and AD eyes. A number of different conditions were 
explored in the attempt to identify Aβ accumulations within the retina including 
antibodies and dyes specific to Aβ, antibody concentrations, incubation times and 
antigen retrieval methods. Despite detecting Aβ in other areas of the eye, difficulties 
were experienced in the detection of Aβ within the neural retinal layers.  
In regards to transgenic mice; I first learned how to dissect the mice eyes to 
isolate the retina. Similarly to human tissue, next optimisation of the vascular labelling 
was carried out on the retina of wildtype mice. I then moved on to the identification of 
retinal Aβ within transgenic and wildtype mice exploring a number of different 
conditions as with research on human retinal tissue. 
 Given the positive results found by other experimental studies (La Morgia et 
al., 2016; Koronyo-Hamaoui et al., 2011); I replicated their protocols in order to 
attempt to label Aβ deposits within the retina.  
Finally I investigated formic acid as an antigen retrieval method on cross-
sections of the eyes from human and transgenic mice. Previous antigen retrieval 
focussed on heat induced citrate buffer, formic acid retrieval was explored as it has 
been described to enhance Aβ detection (Cummings et al., 2002; D'Andrea et al., 
2003).  
 
Human Samples  
Human donor eyes were obtained from Moorfields Eye Hospital, London. Eyes were 
fixed in 4% PFA and stored at 4°C. Donor eyes may lack the cornea due to corneal 
transplantation. Paraffin-embedded cross-sections of human eyes were obtained 
from University College London (UCL) Pathology Department, London. Eyes were 
fixed in 4% PFA, embedded in paraffin and sectioned. Paraffin-embedded sections 
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were stored at room temperature (RT). Sagittal sections of thickness 4µm and 10µm 
were used. Brain slices were obtained from Queen Square Brain Bank for 
Neurological Disorders, UCL, London. Samples were embedded in Optimal Cutting 
Temperature (OCT) compound, frozen and sectioned. Frozen samples were stored 
at -80°C. Brain slices of thickness 10µm were used. AD samples were confirmed with 
the condition upon post-mortem examination of the brain. AD samples and healthy 
control eyes were age-matched in experiments. 
 
Table 1. Details on human samples. AD-Alzheimer’s disease, UCL-University College London, PFA-
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death 
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Mice Samples  
The eyes from 9-month old double mutated transgenic mice and wildtype littermates 
were obtained from Lundbeck. Mice were the APP/PS1-21 model of AD which harbour 
mutations in amyloid precursor protein (APP KM670/671NL (Swedish)) and 
presenilin-1 (PS1 L166P) genes. Presenilin-1 is a core protein found in the γ-
secretase complex which is involved in the production of Aβ peptides. Mutations in 
these genes are associated with early-onset AD and result in elevated Aβ peptides, 
particularly Aβ42 leading to increased plaque formation. Eyes were fixed overnight in 
4% PFA and transferred to phosphate buffered saline (PBS) containing sodium azide 
and stored at 4°C. Mice eyes obtained from University College London were the 
APP/PS1 (TASTPM) model of AD. This model has mutations in APP (APP 
KM670/671NL (Swedish)) and presenilin-1 (PSEN1 M146V) genes. Mice were aged 
14-16 months and eyes were perfused fixed with 4% PFA and stored at 4°C. Paraffin-
embedded cross-sections of mice eyes obtained from University College London 
were the APP/PS1 (TASTPM) model of AD, mutations as previously described. Eyes 
were fixed in 4% PFA, embedded in paraffin and sectioned. Paraffin-embedded 
sections were stored at RT. Mice were aged 21-25 months and sections were of 
thickness 10µm. 
Sample WT/TG Tissue type Source Treatment Age 
1  WT Flat-mount 
retina 
Lundbeck Fixed in 4% PFA 
overnight then 




2 WT Flat-mount  
retina 
Lundbeck Fixed in 4% PFA 
overnight then 








Lundbeck Fixed in 4% PFA 
overnight then 




4  WT Flat-mount 
retina 
UCL  Perfused fixed with 
4% PFA 
16 months 





UCL  Perfused fixed with 
4% PFA 
16 months 
6  WT Flat-mount 
retina 
UCL  Perfused fixed with 
4% PFA 
16 months 





UCL  Perfused fixed with 
4% PFA 
14 months 
8  WT Flat-mount 
retina 





Table 2. Details on mice samples. WT-wildtype, TG-transgenic, APP-amyloid precursor protein, PS1-
presenilin-1, UCL-University College London, PFA-paraformaldehyde, PBS-phosphate buffered saline, 
(-) information not available. 
 
Dissection & Histological Preparation of Mice & Human Eyes 
Both human donor eyes and transgenic mice eyes were initially washed 2 times for 5 
minutes with PBS. To generate sections of flat-mount retina, the anterior portion of 
the eye was removed and retina isolated by dissection. Vitreous humour was removed 
as much as possible manually unless stated otherwise. Where enzymatic treatment 
was used to digest vitreous humour, tissue was treated with hyaluronidase (type I-S) 
for 10-30 minutes then washed three times for 10 minutes with phosphate buffered 
saline (PBS) (Koronyo-Hamaoui et al. 2011). 
 
Immunohistochemistry in Mice and Human Tissue 
Deparaffinization 
Tissues are embedded in paraffin wax to preserve tissue morphology, this wax must 
be removed before immunohistochemistry. Paraffin-embedded cross-sections of 
eyes were deparaffinised through a series of xylenes, hydrated through 100%, 90% 
and 70% ethanol solutions and washed in distilled water. Next cross-sections were 
washed with washing buffer (PBT - PBS containing 0.1% Triton X-100, 0.5% bovine 
serum albumin (BSA), 1mM CaCl2 and 1mM MgCl2). Washing buffer was used in all 
washes unless otherwise stated. CaCl2 and MgCl2 was present in all samples which 
vasculature was labelled. 
Antigen Retrieval & Blocking 
The fixation process is necessary to preserve the tissue structure however cross-links 
form between proteins during this process and this masks antigenic sites within the 
transferred to PBS 
containing sodium 
azide 




Lundbeck Fixed in 4% PFA 
overnight then 




10  WT Cross-section 
of eye 
UCL Fixed in 4% PFA and 
embedded in paraffin 
21 months 





UCL Fixed in 4% PFA  and 




tissue. Antigen retrieval can be used to expose epitopes, allowing antibodies to bind. 
Where antigen retrieval was used, flat-mount retinal samples were subjected to 9 
minutes at 96°C in a water bath and cross-sections of eyes and brain slices for 9 
minutes in a microwave (900 Watt) avoiding boiling. All experiments with antigen 
retrieval involved heated citrate buffer apart from one experiment on human and mice 
cross-sections which investigated formic acid as an antigen retrieval method. A 
homemade citrate buffer was used (10mM Citric Acid, 0.05% Tween 20, adjusted to 
pH6.0 using 1M NaOH) unless otherwise stated. As previously mentioned, one 
experiment was conducted using 70% formic acid. Cross-sections of human and mice 
eyes were incubated for 10 minutes at RT under a fume hood in this case. Samples 
were then washed 2 times for 5 minutes with PBT. Samples were blocked with a 
solution of 5% goat serum diluted in washing buffer to prevent non-specific binding of 
antibodies and increase the signal-noise ratio. Incubation with blocking solution was 
for 2 hours at 30°C for flat-mount tissue or 1 hour at RT for cross-sections. Samples 
were then washed 2 times for 6 minutes in PBT.  
 In the replicated protocols; the protocol by La Morgia et al. (2016) involved 
antigen retrieval with modified citrate buffer (pH 6.0) diluted (1:10) in distilled water 
for 1 hour at 96°C. Human samples were blocked with PBS containing 20% goat 
serum and 0.05%Triton X-100 for 1 hour at RT. The protocol by Koronyo-Hamaoui et 
al. (2011) involved antigen retrieval with modified citrate buffer (pH 6.0) diluted (1:10) 
in distilled water for 9 minutes at 96°C. Human and mice samples were blocked with 
PBS containing 20% goat serum and 0.05% TritonX-100 for 1 hour at RT. 
Immunolabelling in Human Tissue 
During various experiments flat-mount retinal or Bruch’s membrane samples may 
have been incubated with a combination of primary antibodies including anti-Aβ 
mouse monoclonal antibody 6E10 (1:100), anti-Aβ rabbit polyclonal antibody CN3 
(1:1000) and biotinylated Ulex europaeus agglutinin-I (UEA-I) (1:100) diluted in PBT. 
Incubations were for 4 hours at 30°C or overnight at 4°C. Temperature was increased 
in order to make the tissue more permeable or a longer incubation time was to allow 
more time for penetration of the antibody into the tissue. Samples were then washed 
8 times for 5 minutes. Efficient washing removes any unbound antibodies to prevent 
non-specific signal. Secondary antibodies included Alexa Fluor 488 goat anti-mouse 
IgG1 (1:200), Alexa Fluor 546 goat anti-rabbit IgG (H+L) (1:200) and Alexa Fluor 647 
streptavidin conjugate (1:200) diluted in PBT. Incubation time with secondary 
antibodies was for 2 hours at 30°C. Samples must be kept in dark conditions from 
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addition of the secondary antibody. Samples were then washed 8 times for 5 minutes 
with PBT. 
Cross-sections of human eyes may have been incubated with anti-Aβ mouse 
monoclonal antibody 6E10 (1:100), and biotinylated UEA-I (1:100) for 1 hour at RT or 
2 hours at 30°C. Samples washed 3 times for 5 minutes with PBT. Secondary 
antibodies included Alexa Fluor 488 goat anti-mouse IgG1 (1:200) and Alexa Fluor 
647 streptavidin conjugate (1:200). Incubations were for 1 hour at RT or 2 hours at 
30°C. Samples washed 3 times for 5 minutes with PBT.  
Brain slices were incubated with anti-Aβ antibody 6E10 diluted in PBT for 1 
hour at RT. Washed 3 times for 5 minutes. Secondary antibody used was Alexa Fluor 
488 goat anti-mouse IgG1 (1:200) diluted in PBT and incubated for 1 hour at RT. 
Washed 3 times for 5 minutes. Then stained with curcumin solution (2 mg curcumin 
in 2 drops of NaOH) diluted in PBS to make a concentration 0.1 mg/ml. Incubated for 
10 minutes at RT then washed 3 times for 5 minutes in PBS. 
In replicated protocols; the protocol by La Morgia et al. (2016) involved primary 
antibodies which were diluted in PBS with 2% blocking solution and incubated for 72 
hours at 4°C. Secondary antibodies were diluted in PBS and incubated for 1 hour at 
37°C. All washes were as previously mentioned but with PBS. The protocol by 
Koronyo-Hamaoui et al. (2011) involved primary antibodies which were diluted in PBS 
containing 10% blocking solution for 48 hours at 4°C. Secondary antibodies were 
diluted in PBS and incubated for 1.5 hours at RT. Samples were then treated with 
0.3% Sudan Black B (SBB) diluted in 70% ethanol for 10 minutes at RT. Samples 
were washed 3 times for 5 minutes in 70% ethanol and 2 times for 5 minutes in PBS. 
Next samples were labelled with curcumin solution (2 mg curcumin in 2 drops of 
NaOH) diluted in PBS to make a concentration 0.1 mg/ml. Incubated for 10 minutes 
at RT then washed 3 times for 15 minutes in PBS. All other washes were as previously 
mentioned but with PBS.  
Nuclei was stained with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) 
(1:1000) for 15 minutes at RT for cross-sections and brain slices and 30 minutes at 
RT for flat-mount tissue. One experiment involved HAP labelling using Osteosense 
(1:10) which was added with DAPI. Samples were washed for 3 times for 5 minutes 
for cross-sections or 5 times for 5 minutes for flat-mount tissue in PBS and mounted 
using Vectashield containing No DAPI. Coverslips were added and sealed with nail 
varnish. Slides were stored in dark conditions at 4°C after immunostaining procedure. 
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Immunolabelling in Mouse Tissue 
Flat-mount retinal samples from mice may have been incubated with a combination 
of primary antibodies including anti-Aβ mouse monoclonal antibody 6E10 (1:100), 
anti-tau rabbit polyclonal antibody (1:1000) and biotinylated Isolectin-B4 (1:100) for 4 
hours at 30°C. Washed 8 times for 5 minutes with PBT. Secondary antibodies 
included Alexa Fluor 488 goat anti-mouse IgG1 (1:200), Alexa Fluor 568 streptavidin 
conjugate (1:200), Alexa Fluor 647 streptavidin conjugate (1:200) and Alexa Fluor 546 
goat anti-rabbit IgG (H+L) (1:200). Incubation time for secondary antibodies was for 
2 hours at 30°C. Samples washed 8 times for 5 minutes with PBT. DAPI staining and 
mounting as previously mentioned. 
 Cross-sections of mice eyes were incubated with anti-Aβ mouse monoclonal 
antibody 6E10 (1:100) and biotinylated Isolectin-B4 (1:100) for 1 hour at RT.  Samples 
washed 3 times for 5 minutes with PBT. Secondary antibodies included Alexa Fluor 
488 goat anti-mouse IgG1 (1:200) and Alexa Fluor 647 streptavidin conjugate (1:200). 
Incubation was for 1 hour at RT. Samples were then washed 3 times for 5 minutes 
with PBT. DAPI staining and mounting as previously mentioned. 
In replicated protocol by Koronyo-Hamaoui et al. (2011); primary antibodies 
which were diluted in PBS containing 10% blocking solution and incubated overnight 
at 4°C. Secondary antibodies were diluted in PBS and incubated for 1 hour at RT. 
Samples washed as previously mentioned in PBS. DAPI staining and mounting as 
previously mentioned.  
In all experiments negative controls were treated with an identical protocol 
however with omission of primary antibody to assess non-specific binding. Where the 
association with Aβ deposits and retinal vasculature was investigated, vasculature 













Type Dilution Source 
6E10 for Aβ (amino 





CN3 for Aβ (amino 













(1:100) Vector Labs 
(B-1065) 






(1:100) Vector Labs 
(L2140) 
Anti-human Tau Rabbit polyclonal 
antibody 
(1:1000) DAKO (A0024) 




(1:200) Invitrogen  
(A-21121) 
Alexa Fluor 546 goat 
anti-rabbit IgG (H+L) 
Goat polyclonal 
antibody 
(1:200) Invitrogen  
(A-11010) 
Streptavidin, Alexa 
Fluor 647 conjugate 
Streptavidin (1:200) Invitrogen (S21374) 
Streptavidin, Alexa 
Fluor 568 conjugate 
Streptavidin (1:200) Invitrogen (S11226) 
 
Reagent Source  
1X Phosphate Buffered Saline (PBS) 
(pH7.4) 
Gibco (10010-015) 
Triton X-100 Sigma-Aldrich (MKBW8386) 
Bovine Serum Albumin (BSA) Sigma-Aldrich (A7906) 
Hyaluronidase (type-1) Sigma-Aldrich (H3506) 
Citric acid, anhydrous Sigma-Aldrich (251275) 
Tween-20 Sigma-Aldrich (P1379) 
Sodium hydroxide (NaOH) Sigma-Aldrich (221465) 
Citrate Buffer (modified) DAKO (S1699) 
Formic Acid Fisher Scientific (F/1900/PB15) 
Goat serum Sigma-Aldrich (G9023) 
CaCl2 Sigma-Aldrich (C-4901) 
MgCl2 BHD (101494V) 






Dye (1:10) Perkin Elmer 
(NEV10020EX) 
Sudan Black B Dye 0.03% Sigma-Aldrich 
(199664) 
DAPI Dye (1:1000) Thermo Scientific 
(62248) 
Table 4. List of immunolabelling agents used in immunohistochemistry.  
 
Microscopy  
Results were obtained using Leica Sp8 confocal microscope and LAS AF Leica 
Confocal Imaging Software. Optimal settings were established for each individual 
channel used. When optimal microscope settings were established, these settings 
were used to take all images during individual experiments. When no specific signal 
was being detected in the red channel, it may have been utilised to view tissue 
architecture and autofluorescence. During viewing on the microscope, the whole 
tissue was analysed and representative images were taken. In regards to the analysis 
of flat-mount tissue, when assessing different conditions in an experiment the same 
region of the retina was imaged in each case. Fluorescent images were taken with 
20X dry, 40X oil, 63X oil and 100X oil objective lens. Associations of specific labelling 
were distinguished by visual analysis and analysed in depth for specificity. The 
different channels used were merged to form a final image. Scale bars were applied 
on fluorescent images and processing was done using Adobe Photoshop CS6. For 
consistency, any vascular labelling detected with Alexa Fluor 568 streptavidin 














Human - Cross-sections of Eyes  
In order to investigate how Aβ was related to the retinal vasculature, the retinal blood 
vessels needed to be visualised. To determine the best concentration for retinal 
vascular labelling in human tissue, a series of different concentrations of a human 
vascular marker were investigated. Figure 5 shows results from cross-sections of an 
eye from a healthy control individual labelled using Ulex europaeus agglutinin–I (UEA-
I) (magenta) concentrations (1:50), (1:500) and (1:1000). One cross-section from the 
same eye was used as a negative control and was treated with PBT instead of UEA-
I to assess non-specific binding. When a cross-section of the human eye was labelled 
with (1:50), retinal and choroidal vasculature is clearly labelled (Fig.5A & E). Retinal 
layers can be distinguished by the nuclear labelling with DAPI (blue), blood vessels 
are labelled within the ganglion cell layer (GCL) and inner nuclear layer (INL) (Fig.5A). 
Vascular labelling was detected in the choriocapillaris (CC) and larger vessels within 
the choroid (Fig.5E). The cross-section labelled with UEA-I concentration of (1:500) 
portrays faint labelling of blood vessels in the retina and choroid (Fig.5B & F) and 
relatively no vasculature labelling can be seen with a UEA-I concentration of (1:1000) 
(Fig.5C & G). No retinal or choroidal vasculature labelling can be seen in negative 
controls of retina and choroid (Fig.5D & H). Based on these findings, an efficient UEA-
I concentration for vasculature labelling was determined to be between (1:50) and 
(1:500). As a result, all further human vasculature was visualised using a UEA-I 






































































































































































































































































































































































































































































































































Next cross-sections of an eye from a healthy control individual were 
immunolabelled with an anti-Aβ antibody to detect Aβ. Spherical structures 
(spherules) within drusen were labelled with the anti-Aβ antibody (Figure 6). These 
cross-sections were subjected to 9 minutes of antigen retrieval with heated citrate 
buffer and labelled with the anti-Aβ monoclonal antibody 6E10, human vasculature 
marker UEA-I and nuclei stain DAPI. Aβ labelling was detected within drusen (arrow) 
and a vast amount of labelling was detected within the sclera (S) (Fig.6A). The same 
druse at a higher magnification shows numerous spherical forms of Aβ labelling 
(Fig.6B). No Aβ aggregates were detected in the retinal layers with the 6E10 antibody 
(Fig.6D). To assess the specificity of the secondary antibody for the 6E10 antibody, 
the negative control cross-section was subjected to vasculature labelling with UEA-I 
but no 6E10 was used. No Aβ labelling was detected within the negative control cross-
section (Fig.6C & E). Blood vessels (magenta) can be seen throughout the choroid 




Figure 6. Amyloid beta (Aβ) staining on cross-sections of a healthy control human eye. Cross-
sections were stained with anti-Aβ antibody: 6E10 (green), vasculature marker: UEA-I (magenta) and 
nuclei marker: DAPI (blue). (A) Representative image of Aβ labelling detected within druse (arrow) and 
sclera. (B) Higher magnification image of spherical Aβ labelling within druse. (C) No labelling was 
detected in drusen in the negative control cross-section. (D) No Aβ plaque-like accumulations were 
detected in the retina. (E) Negative control image of the retina. NFL-nerve fiber layer, GCL-ganglion cell 
layer, IPL-inner plexiform layer, INL-inner nuclear layer, OPL-outer plexiform layer, ONL-outer nuclear 
layer, PL-photoreceptor layer, RPE-retinal pigment epithelium, C-choroid and S-sclera. 
 
Antigen retrieval is used to unmask epitopes and allow antibodies to bind more 
efficiently to proteins of interest. Different antigen retrieval incubation times with 
heated citrate buffer were investigated shown in Figure 7. Cross-sections from a 
human control eye were subjected to 3, 6, 9 and 18 minutes of antigen retrieval with 
heated citrate buffer. A negative control slide was subjected to 9 minutes of antigen 
retrieval and processed exactly as the other slides with omission of the anti-Aβ 
antibody 6E10. A progressive increase in 6E10 labelling was detected in the retina, 
drusen and sclera of cross-sections as antigen retrieval time was increased. Cross-
sections which were subjected to 3 and 6 minutes of antigen retrieval show slight 
background labelling of 6E10 antibody in the retina (Fig.7A and D), 9 minutes antigen 
retrieval increases labelling of the whole tissue (Fig.7G) and 18 minutes shows a 
dense labelling of the whole tissue (Fig.7J). No Aβ labelling within the retinal layers 
was deemed specific from these images. No 6E10 labelling was detected in the 
negative control retina (Fig.7M). Within drusen, spherules were labelled in cross-
sections subjected with 3-18 minutes of antigen retrieval (Fig.7B, E, H and K). In 
regards to the sclera, an increase in 6E10 labelling was detected as antigen retrieval 
time increased (Fig.7 C, F, I and L). When comparing 6E10 labelling in drusen and 
sclera to retinal labelling, the labelling within drusen and sclera was deemed specific. 
This was due to the signal from the 6E10 antibody within drusen and sclera with 3 
(Fig.7B and C) and 6 minutes (Fig.7E and F) of antigen retrieval is much stronger than 
the background signal in retina (Fig.7A and D). No labelling was detected in the retina, 
drusen or sclera of the negative control cross-section (Fig.3M-O). Vasculature was 






Figure 7. Different antigen retrieval incubation times with heated citrate buffer on cross-sections 
from a healthy control human eye. Cross-sections were stained with anti-Aβ antibody 6E10 and DAPI 
for nuclei. (A-C) Representative images of 3 minutes incubation time on retina, drusen and sclera 
respectively, (D-F) 6 minutes incubation time, (G-I) 9 minutes incubation time and (J-L) 18 minutes 
incubation time. An increase in labelling was detected as antigen retrieval incubation time increased. (M-
O) Negative control images. No vascular marker was used in this experiment. NFL-nerve fiber layer, 
GCL-ganglion cell layer, IPL-inner plexiform layer, INL-inner nuclear layer, OPL-outer plexiform layer, 
ONL-outer nuclear layer, PL-photoreceptor layer, RPE-retinal pigment epithelium, BM-Bruch’s 
membrane, C-choroid and S-sclera. 
 
Cross-sectional samples from a healthy control eye were stained with the anti-
Aβ antibody 6E10 (green) and Osteosense (magenta), a dye which labels 
hydroxyapatite (HAP) (Figure 8). HAP was investigated due to its presence in drusen 
and to explore its association with Aβ (Thompson et al., 2015). Spherical labelling of 
both Aβ and HAP was present within the choroid (Fig.8A, B and C). The three-
dimensional organisation of the spherules labelled for Aβ and HAP can be seen in 
(Fig.8C). The sclera was labelled with Aβ and HAP (Fig.8D-E). The sclera was more 
densely labelled with HAP (Fig.8D’’) than Aβ (Fig.8D’). In all images HAP labelling 
appears to be more abundant than Aβ. Co-localisation of HAP & Aβ was detected on 
individual spherules (arrows) (Fig.8B, C and E). These samples were not subjected 

















































































































































































































































































































































































































































































































































An intracellular Aβ labelling was detected in the GCL of the retina (Figure 9). 
Cross-sections from a healthy control human eye were subjected to the series of 
different antigen retrieval incubation times with heated citrate buffer as in Figure 7. 
The intracellular anti-Aβ antibody 6E10 (green) labelling was detected in ganglion 
cells at 9 and 18 minutes (Fig.9A and B) of antigen retrieval. This labelling was 
detected in the optic disc area to mid peripheral retina. Nerve fibers also appeared to 
be labelled at an area near the optic nerve (Fig.9C). This intracellular labelling 
appears to be distinct from melanopsin ganglion cell (arrow) autofluorescence which 
appear with red pigments (Fig.9E). No intracellular ganglion cell labelling was 
detected in the retina when subjected to 3 (Fig.9F) or 6 minutes (Fig.9G) of antigen 
retrieval or in the negative control (Fig.9H). No Aβ plaque-like accumulations were 




Figure 9. Ganglion cell labelling in cross-sections of a healthy control human eye. Cross-sections 
were subjected to different antigen retrieval incubation times as in Figure 7. Sections were stained with 
anti-Aβ antibody 6E10 (green) and DAPI for nuclei staining (blue). Aβ labelling was detected in cell 
bodies of cells located within the ganglion cell layer (GCL) of the retina in cross-sections which were 
treated to 9 and 18 minutes of antigen retrieval with heated citrate buffer (A & B respectively). (C) Aβ 
labelling also detected in cell bodies and nerve fibers at an area near the optic disc. (D & E) Higher 
magnification images of cell body labelling, intracellular Aβ labelling is distinct from melanopsin ganglion 
cells which present red pigments (arrow). No labelling within the GCL was detected in cross-sections 
which were subjected to 3 (F) and 6 (G) minutes of antigen retrieval or in the negative control (H). NFL-
nerve fiber layer, GCL-ganglion cell layer, IPL-inner plexiform layer, INL-inner nuclear layer, OPL-outer 
plexiform layer, ONL-outer nuclear layer and PL-photoreceptor layer. 
 
Next replication of a protocol from a publication which reported success in the 
identification of Aβ plaques within the retina of both AD and healthy control eyes was 
carried out. I compared three different protocols on cross-sections from a healthy 
control human eye. All samples were subjected to antigen retrieval with either 
homemade or a modified citrate buffer depending on the protocol used. The first 
protocol used was one in which I previously obtained Aβ labelling within drusen 
(Fig.6). Similarly to previous findings, spherical structures were present in drusen 
(Fig.9D) with the 6E10 antibody but no labelling was detected in retinal layers 
(Fig.9A). The next protocol was one in which I previously got labelling within the retinal 
vessels in flat-mount retina (Fig.12). Results were similar to the previous protocol with 
Aβ labelling detected within drusen (Fig.9E) but not within the retina (Fig.9B). The last 
protocol was a replication from a publication (‘Melanopsin Retinal Ganglion Cell Loss 
in Alzheimer Disease’ by La Morgia et al. (2016)) which had reported successful 
identification of Aβ deposits within the retina of AD and age-matched control 
individuals. This protocol involved a long and harsh antigen retrieval method, which 
appeared to make the antibodies adhere to the tissue non-specifically. As a result, 
the whole tissue was labelled and no specific labelling could be detected within the 





Figure 10. Comparison of three different protocols of Aβ immunostaining on cross-sections from 
a healthy control human eye. Sections were stained with anti-Aβ antibody: 6E10 (green), vasculature 
marker: UEA-I (magenta) and DAPI for nuclei staining (blue). (A-C) Representative images of retina and 
(D-F) drusen. (A & D) Protocol 1 – where previous Aβ labelling was detected in drusen (Fig.6). No Aβ 
labelling was detected in the retina (A), Aβ labelling was detected within drusen (D). (B & E) Protocol 2 
– where Aβ labelling was detected within flat-mount retinal tissue (Fig.12). No Aβ labelling detected in 
the retina (B), Aβ labelling was detected within drusen (E). (C & F) Protocol 3 – adapted from a publication 
(‘Melanopsin Retinal Ganglion Cell Loss in Alzheimer Disease’ by La Morgia et al. (2016)). Whole tissue 
appears to be labelled within the retina (C) and druse (F). No specific labelling could be detected. NFL-
nerve fiber layer, GCL-ganglion cell layer, IPL-inner plexiform layer, INL-inner nuclear layer, OPL-outer 
plexiform layer, ONL-outer nuclear layer, RPE-retinal pigment epithelium, BM-Bruch’s membrane and C-
choroid. 
 
All previous antigen retrieval methods have focused around the heated citrate 
buffer method. Towards the end of my project I investigated another method of 
antigen retrieval; formic acid. Figure 11 shows results from cross-sections of the eyes 
from an individual who suffered from dementia (subtype was unknown) and an age-
matched control individual. Samples were treated with heated citrate buffer (Fig.11A-
F), formic acid (Fig.11G-O) or no antigen retrieval (Fig.11P-S). Citrate buffer was used 
as a positive control as we know from previous results that Aβ labelling is present in 
drusen and sclera with heat induced antigen retrieval using citrate buffer. Similar to 
previous results, Aβ was detected in drusen both within the dementia sample (Fig.11B 
and C) and age-matched control (Fig.11F). Spherules labelled with Aβ are also 
present beneath Bruch’s membrane (Fig.11F). Intracellular Aβ labelling was detected 
within the retina of the age-matched control sample (Fig.11D and E) but not in the 
retina of the dementia sample (Fig.11A). Similarly to the previous ganglion cell 
labelling, this labelling was only apparent near the optic disc area to mid periphery of 
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the retina. In the samples which were treated with formic acid, Aβ labelling was 
detected in an area of the retina in the age-matched control sample (Fig.11K and M). 
This may be an intracellular labelling as previously found or possibly clusters of 
vascular-related deposits as a vessel is located adjacent to the labelling. To 
distinguish between a melanopsin ganglion cell and this possible intracellular ganglion 
cell or vascular-related Aβ labelling, a melanopsin ganglion cell is shown (Fig.11N). 
Melanopsin ganglion cells autofluoresce with red pigments and the 6E10 labelling is 
distinct from this autofluorescence which melanopsin ganglion cells present. Formic 
acid treatment appeared to increase the amount of Aβ labelling within drusen and 
sclera; however, no Aβ labelling other than that mentioned previously (Fig.11D, E and 
M) was identified in the retinal layers in the age-matched control or dementia samples. 
Aβ was detected in drusen in both dementia and age-matched control samples that 
were not subjected to antigen retrieval (Fig.11Q and S); however, at a lesser quantity 
than in other antigen retrieved samples. No Aβ was detected in the retinal layers in 













Figure 11. Different antigen retrieval methods on cross-sections from human AD and age-matched 
control eyes. Sections were stained with anti-Aβ antibody: 6E10 (green), vasculature marker: UEA-I 
(magenta) and DAPI for nuclei staining (blue).  Comparison was made between citrate buffer retrieved 
(A-F), formic acid retrieved (G-O) and non-antigen retrieved samples (P-S). (A, D and E) Representative 
retinal images stained for Aβ with citrate buffer retrieval. Intracellular Aβ labelling detected in GCL in age-
matched control sample (D and E). (G, K, M and N) Formic acid retrieval retinal images. Aβ labelling was 
detected in the retina (K and M). No Aβ was detected in retinal images from non-antigen retrieved 
samples (P and R). (B, C and F) Representative sub-RPE images stained for Aβ with citrate buffer 
retrieval, (I and L) formic acid retrieval and (Q and S) no antigen retrieval. Aβ labelling within drusen was 
detected in all samples. Sclera labelling was also present (I). Sub-RPE and retinal images of negative 
control samples subjected to formic acid retrieval show no Aβ labelling (J & O respectively). NFL-nerve 
fiber layer, GCL-ganglion cell layer, IPL-inner plexiform layer, INL-inner nuclear layer, OPL-outer 
plexiform layer, ONL-outer nuclear layer, PL-photoreceptor layer, RPE- retinal pigment epithelium, BM-
Bruch’s membrane and C-choroid. 
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Human - Flat-Mount Retina & Bruch’s Membrane  
To determine if a relationship between Aβ accumulation and retinal vasculature exists 
in human flat-mount retinal tissue, initially I carried out immunostaining with anti-Aβ 
antibody 6E10 and human vasculature lectin UEA-I. Flat-mount retina and Bruch’s 
membrane from a healthy control individual were labelled with 6E10 and UEA-I in 
Figure 12. No antigen retrieval process was involved. Aβ labelling was detected in 
flat-mount retina; the labelling appears to be in small clusters located in proximity to 
the retinal blood vessels (Fig.12A-D). Due to the distinct pattern of nuclei within the 
retinal layers, these vascular-related Aβ accumulations appeared to be located within 
the inner layers of the retina such as GCL & INL. The distribution of Aβ labelling 
throughout the retinal tissue is shown in an image from a z-stack (Fig.12D), 6E10 
labelling is detected in the midst of the tissue closely related to a retinal blood vessel. 
Similarly in another image from a z-stack, 6E10 labelling can be seen deep within the 
tissue (Fig.12E). A blood vessel can be seen adjacent to the Aβ labelling which may 
resemble extracellular Aβ plaque-like structures. Bruch’s membrane was also labelled 
with 6E10, drusen can be seen labelled (Fig.12G) and a higher magnification image 
of a single druse is shown (Fig.12H). Small spherical structures were identified within 
drusen, similar to the distribution found within drusen in human eye cross-sectional 
samples. No Aβ labelling was detected in negative controls of retinal tissue (Fig.12F) 





Figure 12. Aβ labelling detected within healthy control human flat-mount retina and Bruch’s 
membrane. Retinal and Bruch’s membrane tissue stained with anti-Aβ antibody 6E10 (green), 
vasculature marker UEA-I (magenta) and DAPI for nuclei staining (blue). (A & B) Representative images 
of Aβ labelling detected in association with retinal blood vessels. (C) Higher magnification image showing 
distribution of vascular-related clusters of Aβ labelling. (D and E) Images from z-stacks, sub-images to 
left and bottom show the depth of labelling within the tissue. (D) Aβ labelling in close proximity to retinal 
blood vessel. (E) A possible plaque-like Aβ labelling which appears to be in the midst of the tissue. (F) 
No Aβ labelling was detected in negative control sample of retina. (G) Aβ labelling detected in Bruch’s 
membrane sample. (H) Higher magnification image of Aβ labelling within a single druse. No Aβ labelling 
was detected in the negative control sample (I).  
 
To confirm if this antibody labelling was specific to Aβ, next retinal tissue was 
dual-labelled with another anti-Aβ antibody (CN3) (red) and 6E10 (green) in Figure 
13. The retinal blood vessels and nuclei were also visualised using UEA-I (magenta) 
and DAPI (blue) respectively. No antigen retrieval process was involved. Aβ labelling 
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was detected in retinal flat-mount, similarly to previous findings the accumulations 
were detected in association with the vasculature within the retina. Co-localisation of 
6E10 and CN3 antibodies was present within the retina (Fig.12A-D). When the 
separate channels for 6E10 and CN3 were analysed, the labelling of the two 
antibodies was similar in all cases. Correlating with previous findings, these Aβ 
accumulations appeared to be located within the inner layers of the retina. No Aβ 
labelling was detected in the negative control (Fig.12E). 
Figure 13. Co-labelling with anti-Aβ antibodies (6E10 and CN3) on healthy control human flat-
mount retina. Tissue was stained with anti-Aβ antibodies: 6E10 (green) and CN3 (red), vasculature 
marker: UEA-I (magenta) and nuclei stain DAPI (blue). (A) Image from a z-stack which appears to show 
co-labelling of anti-Aβ antibodies in association with a blood vessel. Sub-images to left and bottom show 
the depth of labelling within the tissue. (B-D) Representative images of co-labelling of 6E10 and CN3 in 
regards to retinal vasculature. (B’, C’ and D’) 6E10 labelling and (B’’, C’’ and D’’) CN3 labelling. (E) No 
labelling was detected in the negative control.  
 
Any Aβ labelling which was previously identified in flat-mount retina was found 
in non-AD samples. Therefore, the next step was to investigate how a non-AD sample 
would compare to an AD sample when stained for Aβ (Figure 14). Aβ (green) was 
detected in one single area of the AD retina (Fig.14A) and labelling was associated 
with a retinal blood vessel. Despite previous findings, no Aβ labelling was detected in 
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the age-matched control retina (Fig.14C) in this case. No 6E10 labelling was detected 
in the negative control samples (Fig.14B and D). 
 
Figure 14. Aβ staining in human flat-mount retina from AD and age-matched control samples. 
Tissue was stained with anti-Aβ antibody: 6E10, vascular maker: UEA-I and DAPI for nuclei labelling. (A 
& C) Representative images from AD and age-matched control respectively. Vascular-related 6E10 
labelling can be seen in (A) from the AD sample; however, no 6E10 labelling was detected in the age-
matched control (C). (B & D) No 6E10 labelling was present in negative control samples. 
 
Another publication which reported an increase in the amount of retinal Aβ 
deposits when comparing AD and age-matched control eyes was conducted by 
Koronyo-Hamaoui et al. (2011). They investigated flat-mount retina with curcumin and 
anti-Aβ antibodies. Replication of the protocol which was used in this study was 
carried out on AD and age-matched control retinas. AD and age-matched control 
retinas were stained with anti-Aβ antibody 6E10 (green) and curcumin dye (red) which 
labels Aβ. No Aβ plaques or deposits were found in the AD samples. There appeared 
to be a lot of 6E10 labelling which was on the surface of the tissue, this was not 
considered to be specific to Aβ. A vascular-associated 6E10 labelling was detected 
(Fig.15S box) in the age-matched control retina. A possible intracellular 6E10 labelling 
39 
 
was apparent (Fig.15A). No co-labelling was detected between 6E10 and curcumin 
whilst curcumin did not appear to label any Aβ-related structures within the retina. 
Sudan Black B (SBB) was used in order to reduce the autofluorescence in the retinal 
tissue. This appeared to work as the autofluorescence of melanopsin ganglion cells 
(arrows) and pigments (i.e. Fig.15M) in the tissue is present in samples which were 
not treated with SBB. No obvious differences were detected between antigen 
retrieved and non-antigen retrieved samples. No 6E10 or curcumin labelling was 




Figure 15. Co-staining with anti-Aβ antibody 6E10 and curcumin on flat-mount retina from AD and 
age-matched control samples. Comparison between antigen retrieved and non-antigen retrieved 
tissue was investigated and the ability of Susan Black B (SBB) dye to quench the autofluorescence. 
Tissue was stained with anti-Aβ antibody: 6E10 (green), curcumin (red), vascular marker: UEA-I 
(magenta) and nuclei stain: DAPI (blue). (A-L) Representative images from AD retina subjected to the 
various conditions and (M-X) images from the age-matched control retina. No Aβ plaque-like structures 
were detected in AD samples, the only 6E10 labelling which was deemed specific was the vessel-
associated labelling seen in insets in age-matched control sample (S) and a possible intracellular 
labelling (A). Curcumin did not appear to label any Aβ specific structures. Red pigments which appeared 
individually (i.e. (M)) and within melanopsin ganglion cells (arrows) are present in tissue not subjected to 
SBB treatment. (C. F, I, L, O, R, U and X) Images from negative control samples. 
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Human - Brain Slices  
Brain slices from AD and age-matched control individuals were used as a positive 
control to assess how retinal Aβ labelling compares to cerebral Aβ plaques. Brain 
slices were initially stained with 6E10 (green) and DAPI (blue) seen in Figure 16. 
Antigen retrieval was investigated, brain slices were subjected to heat induced citrate 
buffer antigen retrieval or no antigen retrieval. Aβ plaques were detected in AD (Fig.16 
A and C) and age-matched control brains (Fig.16E and G). Very few plaques were 
detected within the age-matched control brain compared to numerous found within 
the AD brain. In brain slices subjected to antigen retrieval, 6E10 labelling appeared to 
be increased in the cerebral plaques. An intracellular Aβ labelling was also apparent 
in antigen retrieved samples (Fig.16A and E) but not in non-antigen retrieved samples 
(Fig.16C and G). No Aβ plaques were detected in any of the negative control samples 
(Fig.16 B, D, F and H). Brain slices were then stained with curcumin (Figure 17). Co-
localisation of curcumin and 6E10 was present within brain slices of both AD and age-
matched control samples (Fig.17D-F). Separate channels of 6E10 (green) and 
curcumin (red) labelling were analysed and the staining pattern was similar in all 
cases (Fig.17D’-F’’). Magnified images show the morphology of cerebral Aβ plaques 
(Fig.17A-C and F). Autofluorescence (red) can be seen in all images. Curcumin 
labelling can be distinguished from autofluorescence due to the presence of co-





Figure 16. Brain slices of AD and age-matched control samples labelled with anti-Aβ antibody 
6E10. Brain slices were stained with anti-Aβ antibody 6E10 (green) and DAPI (blue). Antigen retrieval 
was investigated. (A and C) Numerous cerebral Aβ plaques detected in the AD sample and (E and G) 
sparse plaques detected in the age-matched control. (A and E) A cellular 6E10 labelling apparent in 
antigen retrieved samples. (B, D, F and H) No 6E10 labelling detected in any of the negative control 





Figure 17. Brain slices of AD and age-matched control samples labelled with anti-Aβ antibody 
6E10 and curcumin. Brain slices were stained with anti-Aβ antibody 6E10 (green) alone or co-stained 
with 6E10 (green) and curcumin (red) and nuclei stained with DAPI (blue). (A-C) High magnification 
images of 6E10 labelled Aβ plaques from age-matched control (A) and AD samples (B & C). 
Autofluorescence (red) can be seen within plaques. (D-F) Co-labelling of 6E10 and curcumin was 
detected in brain slices of AD individuals. Separate channels of 6E10 labelling (green) (D’, E’ and F’) and 











Transgenic Mice - Flat-Mount Retina  
To visualise the retinal vasculature in mice, the best concentration of a vascular 
marker had to be determined. As with in human tissue, a series of different 
concentrations of Isolectin-B4 which labels murine vasculature were investigated. 
This optimisation experiment was carried out on flat-mount retina of wildtype mice. 
The Isolectin-B4 (magenta) concentrations used were (1:50), (1:500) and (1:1000). 
Nuclei was labelled with DAPI (blue). Retinal vasculature is labelled clearly with the 
Isolectin-B4 concentration (1:50) (Fig.18A), blood vessels can be detected with the 
concentration (1:100) (Fig.18B) and faint labelling can be seen with (1:500) (Fig.18C). 
Based on this experiment I decided to use a concentration of (1:100) for labelling the 
retinal vasculature in flat-mount retinal tissue and cross-sections of mice eyes. 
Figure 18. Isolectin-B4 optimisation in wildtype murine flat-mount retinal tissue. Tissue was stained 
with vascular marker: Isolectin-B4 (magenta) and nuclei dye: DAPI (blue). (A) Representative images of 
retinal vasculature from Isolectin-B4 concentrations of (1:50), (B) Isolectin-B4 concentration of (1:100) 
and (C) Isolectin-B4 concentration of (1:500). 
 
To investigate the presence of retinal Aβ within the transgenic APP/PS1-21 
mouse model of AD, the protocol which identified vascular-related Aβ labelling in 
human flat-mount retina was carried out on mice flat-mount retina. Retinal tissue from 
both a transgenic mouse and their wildtype littermate was stained with anti-Aβ 
antibody 6E10 (green) and blood vessels were visualised using vasculature marker 
Isolectin-B4 (magenta) (Figure 19). Mice were 9 months of age. No 6E10 labelling of 
Aβ plaque-like structures was present in the retinas of transgenic or wildtype mice 





Figure 19. Isolectin-B4 staining in transgenic (TG) APP/PS1-21 and wildtype (WT) murine retina. 
Tissue was stained with anti-Aβ antibody 6E10 (green), Isolectin-B4 (magenta) and nuclei dye DAPI 
(blue). No specific 6E10 labelling was detected in the retina of the TG animal (A) or their WT littermate 
(C) or in negative controls (B & D). 
 
No Aβ was detected in the first experiment involving transgenic mice of age 9 
months, next older mice were investigated to rule out that the previous mice (Fig.19) 
may have been too young to develop Aβ plaques within the retina.  Mice were aged 
16 months and were the APP/PS1 (TASTPM) model of AD (a similar model to 
APP/PS1-21, with a different mutation in the PS1 gene). The same protocol which 
was applied on previous transgenic mice was used. Similar results were found, no 
retinal Aβ accumulations were detected in transgenic or wildtype mice (results not 
shown). 
Given the success in the identification of Aβ plaques found by Koronyo-
Hamaoui et al. (2011), replication of their protocol was performed in order to label 
retinal plaques in transgenic APP/PS1-21 mice. Mice were 9 months of age. The use 
of the enzyme hyaluronidase (typeI-S) was investigated. This enzyme digests any 
vitreous humour which may be left on the sample and may affect antibody penetration. 
Retinal samples were incubated with hyaluronidase (typeI-S) for either 10 or 30 
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minutes. Antigen retrieval was investigated. Samples were stained with anti-Aβ 
antibody 6E10 (green) and anti-human tau antibody (red), Isolectin-B4 (magenta) for 
vasculature labelling and DAPI (blue) for nuclei. Confocal microscope images were 
all taken in the inner retina to assess Aβ identification. No Aβ deposits were detected 
in any of the samples from transgenic (Fig20.A-H) or wildtype (Fig.20I-P) murine 
retinas. A 6E10 labelling (green) was apparent around cell nuclei in (Fig.20A). Tau 
was labelled densely throughout the retinal tissue, nerve fibers were labelled more 
brightly with the tau antibody. No obvious differences were seen in antigen retrieved 
and non-antigen retrieved tissue. It appeared that the use of the enzyme 
hyaluronidase may have been a harsh treatment as some damage was noticed on 
the retinal tissue. No 6E10 or tau antibody labelling was detected in negative control 














Figure 20. Transgenic APP/PS1-21 and wildtype mice flat-mount retina stained for Aβ and tau. 
Mice were 9 months old. Samples stained with anti-Aβ antibody 6E10 (green), anti-human Tau antibody 
(red), Isolectin-B4 (magenta) for vasculature and DAPI (blue) for nuclei. Vitreous digestion and antigen 
retrieval was investigated. Transgenic samples (A-H) and wildtype (I-P). 6E10 labelling was detected 
around cell nuclei (A). No Aβ deposits found. Tau expressed throughout the retinal tissue. TG-transgenic, 
WT-wildtype, AR-antigen retrieval. 
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I then applied the same protocol as previously used on older transgenic 
APP/PS1 (TASTPM) mice (Figure 21). Mice were 14-16 months of age. Samples were 
subjected to vitreous digestion with hyaluronidase (typeI-S) for 20 minutes or no 
hyaluronidase treatment. Confocal microscope images were all taken in the inner 
retina to assess Aβ identification. Antigen retrieval was investigated with samples 
subjected to antigen retrieval with modified citrate buffer or no antigen retrieval 
process. Similarly to the previous experiment, 6E10 labelling (green) was detected 
around cell nuclei (Fig.21A). No other Aβ-specific labelling was detected in any of the 
samples from wildtype or transgenic murine retinas. Vast expression of tau was 
detected in all samples treated with the tau antibody (red). Retinal vasculature 
(magenta) and nuclei (blue) were labelled. No 6E10 or tau antibody labelling was 











Figure 21. Transgenic APP/PS1 (TASTPM) and wildtype mice flat-mount retina stained for Aβ and 
tau. Mice were 14-16 months old. Samples stained with anti-Aβ antibody 6E10 (green), anti-human Tau 
antibody (red), Isolectin-B4 (magenta) for vasculature and DAPI (blue) for nuclei. Vitreous digestion and 
antigen retrieval was investigated. Transgenic samples (A-H) and wildtype (I-P). 6E10 labelling was 
detected around cell nuclei (A). No Aβ plaque-like deposits found. Tau was expressed throughout the 
retinal tissue. TG-transgenic, WT-wildtype, AR-antigen retrieval. 
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Transgenic Mice - Cross-Sections of Eyes 
Approaching the end of my project, I investigated cross-sections of eyes from 
transgenic APP/PS1 (TASTPM) and wildtype mice. Transgenic mice were aged 25 
months and wildtype mice were aged 21 months. I investigated the effect of different 
antigen retrieval methods, using heated citrate buffer and formic acid. One cross-
section from transgenic and wildtype mice had no antigen retrieval process applied. 
Sections were immunostained with anti-Aβ antibody 6E10 (green) and vasculature 
marker Isolectin-B4 (magenta) and DAPI (blue) for nuclei labelling. No Aβ plaque-like 
structures were found in the retina of either transgenic or wildtype mice. An 
intracellular staining was detected in the GCL of the retina in the cross-section of the 
transgenic mouse eye which was treated with citrate buffer (Fig.22A). This was not 
present in the wildtype cross-section treated with citrate buffer (Fig.22B) or in formic 
acid or non-treated sections (Fig.22C and E). No Aβ labelling was detected in formic 
acid (Fig.22C and D) or non-antigen retrieved samples (Fig.22E and F). No 6E10 
labelling was detected in negative control samples (Fig.22G and H). Negative controls 
in this case were treated with formic acid antigen retrieval and no 6E10 antibody was 
applied. The vascular marker did not appear to work in this experiment. 
Figure 22. Immunostaining of Aβ in cross-sections of eyes from transgenic APP/PS1 (TASTPM) 
and wildtype mice subjected to different antigen retrieval methods. Cross-sections were subjected 
to either heated citrate buffer (A and B), formic acid (C and D) or no antigen retrieval (E and F). Sections 
were stained for anti-Aβ antibody 6E10 (green), Isolectin-B4 (magenta) and DAPI (blue) for nuclei. 
Negative controls were treated with formic acid retrieval (G and H). (A) 6E10 labelling was detected in 
ganglion cell layer (GCL) in a transgenic mouse eye cross-section treated with citrate buffer. No 6E10 
labelling was detected in any other samples. TG-transgenic, WT-wildtype, AR-antigen retrieval. NFL-
nerve fiber layer, GCL-ganglion cell layer, IPL-inner plexiform layer, INL-inner nuclear layer, OPL-outer 









The investigation of Alzheimer’s disease-associated pathologies within the human 
retina is a recent area of research. In particular, retinal Aβ deposition has been 
investigated by few studies and inconsistent findings have been reported. My 
research has focused on the identification of Aβ within the retina of humans and 
transgenic mouse models of the AD. A large part of my research involved the 
optimisation of immunohistochemistry techniques. I investigated factors such as 
antigen retrieval methods, antibody concentrations and incubation times in order to 
find the most optimal conditions for Aβ immunostaining.  Based on the most optimal 
conditions, Aβ was identified in various parts of the eye. Aβ labelling was detected in 
both human retinal flat-mount and cross-sectional samples and murine flat-mount 
retinal and cross-sectional samples.  In regards to Aβ within the retina, Aβ aggregates 
were detected in the human retina in both AD and age-matched controls, in this case 
there appeared to be an association between clusters of Aβ deposits and the retinal 
vasculature. No increase in retinal Aβ deposits was found in AD samples when 
compared to age-matched control samples. An intracellular Aβ labelling was detected 
in the retina of both humans and transgenic mice. Aβ labelling was also detected in 
other areas of the eye in human dementia and age-matched control samples such as 
drusen, choroid and sclera. 
Aβ Detection in Drusen, Choroid and Sclera  
The cross-sections of the human eye used in this research were known to possess 
drusen deposits, which can occur naturally in the aging process (Thompson et al., 
2015; Löffler et al., 1995). When these sections were immunostained with the anti-Aβ 
antibody 6E10, labelling was detected within drusen in a spherical like form similar to 
findings within previous publications (Thompson et al., 2015; Anderson et al., 2004; 
Luibl et al., 2006). Aβ labelling was detected in drusen in both dementia (subtype 
unknown) and age-matched control samples. No differences were found in Aβ 
labelling within drusen in dementia and age-matched control samples. The nature of 
the spherules within drusen appear to be diverse, some are not labelled with the Aβ 
antibody but appear black spherical structures (Fig.10D and Fig.11C), others which 
only stain for HAP (Fig.8) and some which are labelled for with both Aβ and HAP 
(Fig8B, C and E). Whilst some druse have no labelling at all (Fig.7K). Aβ labelling was 
also detected in drusen in flat-mount samples of Bruch’s membrane. This labelling 
was in a similar pattern to the labelling identified in drusen in cross-sectional samples, 
small circular structures were present. Aβ labelling within drusen was detected in all 
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samples stained with the 6E10 antibody even if no antigen retrieval process was 
applied. Due to the detection of Aβ in drusen, cross-sections were often used as a 
positive control in experiments involving flat-mount tissue. In this case, cross-sections 
would be treated identical to flat-mount tissue, if Aβ was detected within drusen in 
cross-sections it confirmed that the 6E10 antibody worked. Aβ labelling in spherules 
was also detected around basal areas, within the choroid and sclera. 
Comparisons between drusen and cerebral plaques in AD has shown that the 
two structures share similarities. They may have similar processes of formation, given 
they both have the ability to spontaneously aggregate Aβ. Comparisons have also 
been made between their contents, both structures have been shown to contain 
different forms of amyloid (Kayed et al., 2003, Luibl et al., 2006), have been 
associated with lipids (Koronyo-Hamaouri et al., 2011; Thomspon et al., 2015; Wang 
et al., 2010) and complement components (Yasojima et al., 1999; Johnson et al., 
2001). Therefore research into Aβ deposition in drusen could potentially give an 
insight into the formation of cerebral plaques characteristic of AD. 
Spherules within drusen have been proven to contain HAP, a calcium 
phosphate which is commonly found in bones and teeth. These HAP spherules may 
be coated with a number of different proteins including Aβ (Thompson et al., 2015). 
Similarly, another study reported that Aβ was associated with the outer layer of these 
spherules (Johnson et al., 2002). This concept may explain why a vast amount of 
spherules were labelled with HAP whilst only few were labelled with Aβ. It may also 
explain the co-labelling of HAP and Aβ obtained on individual spherules, these may 
be HAP spherules which are coated with Aβ. In contrast, this co-labelling was 
detected in the choroid and sclera in my research as opposed to within drusen which 
was found in the publications mentioned previously. 
Aβ labelling was detected within the sclera in human cross-sectional samples. 
This was an unexpected finding as there is very little evidence of Aβ deposition within 
the sclera in published data. One study which reported scleral Aβ labelling in 
association with AD found deposits in the sclera of a transgenic mouse model of AD.  
Only few deposits were detected (Koronyo-Hamaoui et al., 2011), whereas in my 
findings the sclera is very densely labelled.  This vast amount of Aβ labelling was 
detected in the sclera of human samples in both dementia (subtype unknown) and 
age-matched controls. Since this scleral labelling was found in both dementia and 
age-matched controls, it is not specifically associated with dementia or AD. When the 
sclera was stained with Osteosense which labels HAP; a calcium phosphate, the 
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sclera was also densely labelled. This would suggest that the sclera may be calcified. 
Given the association between HAP and Aβ within spherules in drusen, a possible 
link may exist between calcification of the sclera and Aβ labelling. However, the focus 
of my research was retinal Aβ deposition therefore this was not investigated further. 
Aβ Detection within the Human Retina 
Much controversy exists regarding the presence of Aβ deposits within the retina. In 
human flat-mount retina, labelling was detected in an AD and age-matched control 
sample. Aβ labelling in both cases appears to be associated with retinal blood vessels.  
It is difficult to establish the retinal layers when viewing flat-mount tissue; however, 
given the distinct nuclei distribution within the retina, it was estimated that the 
vascular-related Aβ labelling was located in the inner retinal layers. Vascular-related 
Aβ deposits were detected in the retina of a non-AD individual; however, any retinal 
tissue which was labelled was from one individual. This finding was not surprising as 
sparse Aβ deposits have been found in the retina of healthy eyes by other studies (La 
Morgia et al., 2016; Koronyo et al., 2017). Few Aβ plaques were also found in the 
brain of healthy individuals which supports that existence that low levels of Aβ 
deposits may be present within the retina and brain of healthy individuals. 
In regards to vascular-associated Aβ labelling in the retina of individuals with 
AD, this was only present on one account where few deposits were located in a single 
area of the retina. Much larger quantities of Aβ deposits would have been expected 
in an AD sample if retinal deposition correlated with cerebral deposition. Although 
similarly to the vascular-related Aβ labelling in non-AD samples, any AD retinal flat-
mount tissue was from a single individual. Results may have differed if more AD 
samples were analysed.  
I investigated co-staining of two anti-Aβ antibodies (6E10 and CN3) in a non-
AD sample. Co-localisation of the antibodies was present in various areas of the 
retinal tissue. This provided confirmation that the labelling was specific to Aβ-related 
structures. However, samples were also co-stained with anti-Aβ antibody 6E10 and 
curcumin, which is a dye which binds Aβ (Garcia-Alloza et al., 2007). During this 
experiment, sparse 6E10 labelling was detected in vascular-related areas whilst no 
curcumin labelling was detected in any of the samples. The vascular-related Aβ 
labelling with the 6E10 antibody was detected in the age-matched control sample but 
no Aβ deposits were identified in the AD sample. However, co-localisation of the 6E10 
antibody and curcumin on retinal Aβ deposits has been detected by other studies 
(Koronyo-Hamaoi et al., 2011; Koronyo et al., 2017). 
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Aβ deposits have been found associated with the retinal vasculature by other 
studies. One study identified Aβ plaques in clusters which is similar to the distribution 
in my results. They reported abluminal Aβ deposits being the most frequently found 
in AD retinas (La Morgia et al., 2016). Similarly, another study found retinal Aβ 
plaques associated with retinal vasculature particularly in the abluminal position but 
plaques were also detected within blood vessels (Koronyo-Hamaoui et al., 2011). A 
recent study also found Aβ deposits located nearby and inside blood vessels as well 
as along the vessel walls. Again in a similar distribution to my findings, deposits can 
be seen in clusters associated with the vasculature (Koronyo et al., 2017). The 
vascular-related Aβ deposits which were found in my results were located in close 
proximity to retinal vasculature; however, I was not able to distinguish if they were 
located on the outside or within retinal blood vessels. The non-AD individual which 
presented vascular-associated Aβ deposits died from cardiovascular disease, this 
provides further evidence supporting a vascular disease component in AD. Vascular-
associated Aβ deposits may be responsible for the changes in vasculature and blood 
flow which are apparent in the retina during AD (Berisha et al., 2007; Frost et al., 
2013; Williams et al., 2015). The retinal vasculature and cerebral vasculature are 
directly linked and share anatomical and physiological similarities (Patton et al., 
2005). In addition to this, vascular-related Aβ deposition identified within the retina 
reflects a process which occurs in the brain when Aβ is deposited in the cerebral blood 
vessels in the condition cerebral amyloid angiopathy. This condition is commonly 
found in association with AD (Thal et al., 2008) and suggests a further link between 
the vascular Aβ deposition in the retina and brain in AD. 
Results on Aβ deposition in the retina in cross-sectional samples is minimal. 
Research on cross-sections involved mostly healthy control eyes, with one dementia 
sample being analysed. The subtype of dementia was unknown, it is possible that this 
samples was not AD and hence lacked Aβ pathology. Analysis of healthy control eyes 
allowed for the optimisation of Aβ detection within drusen and after optimisation was 
intended to be transferred to AD tissues. Aβ plaques were not expected to be present 
in the retina of healthy control eyes. Despite this, retinas were analysed due to the 
identification of retinal Aβ deposits in healthy control retinas on rare occurrences. A 
possible vascular-related Aβ deposition was detected in one area of the retina in a 
cross-section of a healthy control eye which was subjected to formic acid retrieval. 
The lack of definite AD cross-sectional samples analysed is likely to be responsible 
for the shortage of retinal Aβ deposits identified. 
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An intracellular Aβ labelling was detected in the GCL in cross-sections of the 
eye. This Aβ labelling was apparent in cross-sections which were treated with heat 
induced citrate buffer antigen retrieval. However, the cross-sections which exhibited 
intracellular ganglion cell labelling were from a single non-AD sample and this 
labelling was not present in other non-AD samples which were treated identically. A 
study by La Morgia et al. (2016) reported that a subtype of ganglion cells; melanopsin 
ganglion cells exhibit Aβ immunoreactivity. Melanopsin ganglion cells may exhibit Aβ 
labelling but they also express autofluorescent red pigments when viewed under 
confocal microscope. The ganglion cell labelling most often detected in my results 
was a more intense Aβ labelling and no red pigments were expressed. Therefore I 
believe the ganglion cells detected in my results which were labelled intracellularly for 
Aβ are distinct from melanopsin ganglion cells. Likewise, a cellular labelling was also 
detected in flat-mount retinal tissue which was subjected to citrate buffer retrieval 
process. This appeared to be in the inner layers of the retina therefore could possibly 
have been located in the GCL. A possible cellular or vascular-related labelling was 
detected in the cross-section of a non-AD eye which was subjected to formic acid 
retrieval; however, this was only apparent in a single area of the retina and is distinct 
from the numerous ganglion cells which appear labelled in the citrate buffer treated 
samples. Intracellular Aβ is not well characterised within the human retina, although 
a similar intracellular Aβ immunoreactivity was detected in the GCL in AD retinal 
samples using the 6E10 antibody by another study (Koronyo et al., 2017). Intracellular 
Aβ was also detected with an antibody specific to Aβ42 (12F4), the study concluded 
that intracellular Aβ could be an alternative method of Aβ-medicated toxicity. 
Intracellular labelling was also detected by Koronyo-Hamaoui et al. (2011) in AD post-
mortem retina, it was suggested that this was Aβ40 as the antibody used was specific 
to this Aβ peptide (11A5-B10).  
The replication of two different protocols from experimental studies which 
reported the identification of Aβ deposits in the human retina (La Morgia et al., 2016; 
Koronyo-Hamaoui et al., 2011) did not prove successful in identifying Aβ deposits. 
I analysed the retinas from 1 AD, 1 dementia (subtype unknown) and 5 control 
samples. The AD sample was flat-mount retina and the dementia sample was a cross-
section of the eye. Retinal Aβ deposits were found in many areas in a control sample 
and in one area in an AD sample. In all cases where Aβ deposition within the retina 
was detected, a retinal blood vessel was located nearby. This suggests a link between 
Aβ deposition and the retinal vasculature. As previously mentioned, the lack of retinal 
Aβ deposits located in relation to AD is likely to be due to the low number of definite 
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AD samples analysed. A larger number of AD samples would need to be used to 
determine of retinal Aβ deposition is a pathology associated with AD. 
Aβ Detection within the Human Brain 
Brain slices were used as a positive control in order to compare retinal Aβ deposition 
with cerebral Aβ plaques. Cerebral plaques were much larger in size than any retinal 
deposits which were identified. Plaques within the brain were more numerous in the 
AD sample than Aβ deposits which were found in the retina of the AD eye. When brain 
slices were co-labelled with 6E10 and curcumin, co-localisation was present in Aβ 
plaques; however, this did not occur when the AD retina was labelled with 6E10 and 
curcumin as previously mentioned. This suggests that differences exist in the 
composition of cerebral plaques and retinal deposits consisting of Aβ. A clear 
difference was seen in the brain pathology between the AD and age-matched control 
sample. A large number of plaques were detected in the AD brain whilst few were 
detected in the age-matched control. This is contrasting to the retina where no 
increase in Aβ deposits was detected in AD when compared to age-matched control 
samples. Few plaques were detected in the age-matched control brain which supports 
the idea that cerebral Aβ plaques precede cognitive decline in AD (Price et al., 2009). 
An intracellular labelling was also detected in the brain of AD and age-matched control 
samples which were subjected to citrate buffer antigen retrieval, this labelling was 
similar to what was found in the GCL of human retinal samples. It is possible that this 
intracellular labelling could be due to antibody cross-reactivity as it appears the 
epitope which is recognised by the 6E10 antibody is present on both Aβ and its 
precursor protein APP.  Evidence of this is shown by an experimental group who 
detected a cellular labelling within the brain. When 6E10 labelling was compared with 
an antibody specific to APP, a similar staining pattern was observed. The intracellular 
6E10 labelling appeared to be APP and not Aβ (Aho et al., 2010). Despite this, 
intracellular Aβ in regards to AD has been described. The presence of cellular Aβ is 
better characterised within the brain in regards to AD than within the retina. 
Intracellular Aβ within neurones of the brain is thought to contribute to disease 
progression (LaFerla et al., 2007). The neurotoxic Aβ42 peptide was detected inside 
cell bodies in the brain in a study by Ohyagi et al. (2007). Interestingly, this research 
compared antigen retrieval with heated citrate buffer and formic acid. Aβ was detected 
within cells with the citrate buffer retrieval whilst no cellular labelling was seen using 
formic acid retrieval, these findings within the brain were similar to results I found 
within the retina. Furthermore, intracellular Aβ has been proposed to occur prior to 
and may give rise to cerebral plaques in AD (Oddo et al., 2006; Pensalfini et al., 2014). 
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The pathogenic nature of intracellular Aβ has been characterised in the AD brain; 
however, the intracellular nature of Aβ within the retina needs to be further 
investigated to determine if it is related to AD pathogenesis. 
Aβ Detection in Transgenic Mouse Models of AD 
The presence of Aβ within the retina of transgenic animal models of AD has more 
consistent findings in publications than the presence of Aβ in the human retina in AD. 
Despite this, I was unable to detect any Aβ deposits within the retina of transgenic 
mouse models of AD. The only Aβ-related labelling detected with the 6E10 antibody 
was intracellular, within the inner layers of the retina in flat-mount tissue and located 
in the GCL in cross-sections. The 6E10 labelling in the cross-section of an eye from 
a transgenic mouse was detected in a section which was subjected to heat induced 
citrate buffer antigen retrieval. This was similar to the intracellular labelling within 
human retinal tissue which was also more apparent with this method of antigen 
retrieval. The Aβ labelling in the cross-section shows typical ganglion cell morphology 
with dendrites extending into the inner plexiform layer. A similar staining pattern was 
detected in another study on a transgenic mouse model of AD although the labelling 
in this case was for the Aβ precursor protein APP (Ning et al., 2008). As previously 
mentioned, the 6E10 antibody labels APP as well as Aβ therefore it is possible that 
the labelling in my murine cross-section may be APP and not Aβ.  
Plaques have been observed in the retina of transgenic mouse models of AD 
in a number of studies (Koronyo-Hamaoui et al., 2011; Ning et al., 2008; Perez et al., 
2009; Liu et al., 2009; Tsai et al., 2014; Gupta et al., 2016). After failing to detect any 
plaques in my initial experiment using 9 month old transgenic mice, I investigated age 
as a factor which may have prevented the identification of retinal Aβ deposits. After 
performing the same protocol on older 16 month old transgenic mice, similarly no Aβ 
deposits were found. Furthermore, Aβ plaques were identified in the retina of mice as 
young as 2.5 months old in a similar model of AD (Koronyo-Hamaoui et al., 2011). 
Therefore age could not be responsible for the lack of retinal Aβ deposits detected. 
After failing to detect any Aβ deposits in the retina of transgenic mice using 
methods which detected vascular-associated retinal Aβ in human tissue, I replicated 
a protocol from a publication which reported the identification of retinal Aβ deposits in 
transgenic mice (Koronyo-Hamaoui et al., 2011). Similar to results in the replication 
experiments in human tissue, the replication of the protocol in transgenic mice failed 
to produce successful results in Aβ deposition.  
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 I analysed the retinas from 5 different transgenic mice and their wildtype 
littermates of various ages, 4 were flat-mount retinal tissue and 1 was cross-sections 
of the eye. In order to establish what was responsible for the lack of retinal Aβ deposits 
in transgenic mice, more samples would need to be investigated and alterations made 
to the immunolabelling protocol. The length of my research project did not allow for 
further investigation. Due to the lack of retinal Aβ deposits found in transgenic mouse 
models of AD I could not investigate the relationship between retinal vasculature and 
Aβ deposits. 
To summarise my research, Aβ labelling was detected in regions of the retina 
in both flat-mount and cross-sectional samples of the eye. Where extracellular Aβ 
labelling was detected, in all cases there was a retinal blood vessel in close proximity 
suggesting a link between Aβ deposition and retinal vasculature. Vascular-related Aβ 
deposits were identified in the human retina in both AD and age-matched control 
samples. These deposits were much smaller in size than cerebral Aβ plaques. No 
increase in Aβ deposits were found in AD samples when compared to age-matched 
controls. A complete lack of Aβ deposits were found in the retina of transgenic mouse 
models of AD. Aβ was detected in the sub-RPE region including drusen, choroid and 
sclera although no difference was found between dementia samples and age-
matched controls. An intracellular Aβ labelling was detected in human retina, brain 
and transgenic mouse retina. This appears to be associated with antigen retrieval with 
citrate buffer and was only apparent after an antigen retrieval incubation time of 9 
mins or greater. There is a possibility that this labelling is APP and not Aβ due to the 
same epitopes in Aβ and APP. However, intracellular Aβ is apparent in the brain 
during AD (Pensalfini et al., 2014), therefore this concept occurring within the retina 
should not be ruled out until further clarification is obtained. 
Limitations of My Research 
Immunohistochemistry is a technique which allows identification of proteins of 
interest. Identification of Aβ was possible; however, no quantitative data analysis was 
included in my research project. The ability to determine how much Aβ peptide was 
present in key areas of interest such as vascular-related sites of identification and 
intracellular Aβ labelling or how many areas of Aβ deposition occurred in a single 
retina would have provided more information on the nature of retinal Aβ. 
 Three different agents specific to Aβ were used: anti-Aβ antibodies 6E10 and 
CN3 and the dye curcumin. The antibodies were specific to the same region on the 
Aβ peptide; the N-terminus. These antibodies are unable to distinguish between APP 
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and different forms of the Aβ peptide such as Aβ40 or Aβ42. The use of other 
antibodies which recognise different epitopes on the Aβ peptide and be able to 
distinguish between Aβ peptides and precursor proteins would have provided more 
conclusive results. Curcumin was able to detect cerebral Aβ plaques but no labelling 
was found in the retina. Curcumin labelled Aβ plaques within the retina have been 
described (Koronyo-Hamaoui et al., 2011; Koronyo et al., 2017); however, I only 
investigated curcumin in one experiment so replication may have been needed.  
 The antigen retrieval method mainly used in my research was heated citrate 
buffer. Antigen retrieval by formic acid is the method routinely described in the 
literature in regards to retinal Aβ identification (Ning et al., 2008; Liu et al., 2009; 
Dutescu et al., 2009). I only investigated formic acid as a method of antigen retrieval 
for detection of Aβ in one experiment in human and mice. However, other methods of 
retrieval have been reported successful in retinal plaque detection as Koronyo-
Hamaoui et al. (2011) report Aβ plaques with citrate buffer retrieval. I used citrate 
buffer in the majority of my research as detection of Aβ aggregates within drusen was 
possible with this antigen retrieval method. Although, it is a possibility that differing 
forms of Aβ exist in drusen and retinal Aβ deposits and this may be responsible for 
the lack of retinal deposits detected in many cases. 
Where Aβ labelling was detected in flat-mount tissue, it was often in very few 
areas. Therefore when analysing cross-sections, key pathologies could have be 
missed due to sectioning of the eye. Sectioning a whole eye and immunostaining it 
would have produced more conclusive results in distinguishing the presence of Aβ 
deposition. 
Difficulties were experienced in the identification of retinal Aβ deposition in 
relation to AD therefore the protocols from two experiments studies which reported 
successful findings were replicated. However, the replication of these protocols was 
only possible to a certain extent. The protocols which were carried out on human 
tissue did not result in Aβ plaque-like structures being detected. Although some 
conditions differed between my research and the original research, these included the 
replication protocol which was carried out on cross-sections in my research was 
carried out on flat-mount retinal tissue in the original experimental study (La Morgia 
et al., 2016). Furthermore my analysis was on individuals who were not diagnosed 
with AD. In the experimental study by Koronyo-Hamaoui et al. (2011), the 
hyaluronidase treatment was used on human tissue to digest the vitreous whilst this 
treatment was not used in my experiments on human retina. This study also 
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investigated a number of different agents in the detection of Aβ whilst I only used the 
6E10 antibody and curcumin. I also replicated the protocol used on transgenic mice 
in the publication by Koronyo-Hamaoui et al. (2011). Despite the vast amount of retinal 
deposits found in this publication, no Aβ plaque-like structures were located in the 
retina of transgenic mice in my research. Hyaluronidase treatment was used to digest 
any remaining vitreous residue, in the original research this was performed on fresh 
tissue whilst I did not have access to fresh tissue therefore fixed tissue was used 
instead. A variety of different agents were used to label retinal Aβ in this research 
whilst I only used the 6E10 antibody. It is possible that these conditions may account 
for the lack of deposits found in these experiments. 
In terms of samples used, few AD samples were used in my research. The 
vascular-related Aβ labelling in both AD and age-matched control flat-mount retinal 
tissue were from a single patient in each case. Only one AD retinal flat-mount sample 
was used and cross-sections from one dementia sample of which the subtype was 
unknown. This sample may not have been AD therefore may explain why no retinal 
Aβ accumulations were identified in human cross-sections. A larger sample size 
would have provided more reliable results although the difficulties in obtaining human 
tissue must be considered. 
Furthermore, not all the information for the samples used was available. No 
information was available for the post-mortem time of the human samples, this may 
cause degeneration of the tissue and affect the ability to identify Aβ. No information 
was given on the stage of AD or the length of time in which an individual had the 
condition, there would be different degrees of pathology with progression of AD and 
this may affect the amount of Aβ deposits present in the retina. Finally, the cause of 
death for many of the samples was not available. This would have been useful in 
providing more information on the medical history of the patient samples used. 
One AD brain sample was included in my research as a positive control in 
order to assess how cerebral Aβ plaques appear when immunolabelled and how they 
compare to retinal Aβ deposits. I did not investigate if Aβ plaques were associated 
with the cerebral vasculature, it would have been interesting to explore if cerebral Aβ 
plaques were associated with vasculature in a similar way to the vascular-related Aβ 
deposits which were detected in the retina. The brain which was investigated was not 
from any of the samples in which retina was explored. Ideally it would have been 
better to have the eye and brain of the same individual or transgenic animal to 
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evaluate the comparison of Aβ load within the brain and retina. This would have been 
a true indicator if retinal pathology could be representative of brain pathology in AD. 
I only investigated Aβ accumulation within the retina in association with AD. It 
would have been interesting to evaluate another AD-associated pathology such as 
NFT’s. Although I did explore the expression of tau within retinal tissue, 
immunolabelling for phosphorylated tau would have provided more insight into AD-
associated changes within the retina. 
Conflicting Results in Published Data 
Inconsistent results have been reported in the literature in regards to Aβ within the 
human retina. The differing results may be due to a variety of factors. Different 
immunohistochemistry techniques would account for different results. Antigen 
retrieval methods have different degrees in which epitopes are unmasked, therefore 
certain methods would be better for identifying particular proteins. The state of the 
tissue would affect results, whether fixed or fresh tissue or if cross-sections are frozen 
or embedded in paraffin. Furthermore, differing results may be found in flat-mount 
retinal tissue and cross-sections of the eye. Flat-mount tissue appears to be a more 
reliable indicator of tissue pathology than cross-sections where pathology could 
potentially be missed. Immunohistochemistry techniques would need to be altered for 
tissue type as flat-mount tissue tends to be thicker than cross-sections which may 
affect antibody penetration. Interestingly, both experimental studies which failed to 
detect Aβ in the human AD retina only analysed cross-sections of the eye (Schön et 
al., 2012; Ho et al., 2014). Whereas research studies which successfully identified Aβ 
deposits analysed flat-mount retinal tissue, aside from one study by Koronyo et al. 
(2017) which detected Aβ plaques in cross-sections of the eye and flat-mount retinal 
tissue (Koronyo-Hamaoui et al., 2011; La Morgia et al., 2016; Koronyo et al., 2017;  
Tsai et al., 2014). Therefore, flat-mount retinal tissue appears to produce more 
conclusive results in the detection of Aβ within the retina during AD. 
Conclusion and Future Research 
I detected Aβ labelling in the retina of human and transgenic mouse models of AD. 
An intracellular labelling was detected in human and transgenic animal samples. Aβ 
labelling which appears as plaque-like structures was identified in the retinas of both 
AD and age-matched control samples, in all cases these appeared as clusters of 
deposits associated with retinal vasculature. However, no increase in deposits was 
detected in AD samples when compared to age-matched control samples. A lack of 
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Aβ plaque-like structures were identified in the retina of transgenic mice. Therefore I 
could not investigate how the relationship between retinal blood vessels and Aβ 
detection in the transgenic mouse retina. Given these results, it is not possible to 
conclude that retinal pathology could represent brain pathology in AD. 
 Based on the results I obtained, future research needs to be carried out on the 
relevance of Aβ within the sclera of the eye. Intracellular Aβ within the retina; in 
particular the GCL, needs to be investigated to determine if this contributes to the 
pathogenesis of AD. Finally, more research into the detection of AD-associated 
pathologies in the retina of human AD patients is needed. To achieve this, research 
should ideally include comparison of brain and retina from the same individuals, larger 
samples of AD patients, focusing particularly on flat-mount retinal tissue and using a 
variety of different agents to label pathologies. 
 Currently, the presence of retinal Aβ plaques remains ambiguous. Despite the 
lack of retinal deposits identified in association with AD, I believe the retina should not 
yet be ruled out as representing brain pathology in AD. The retina has advantages 
over the brain as it can be easily accessed and viewed non-invasively. There is 
evidence to suggest that retinal Aβ deposits could be characteristic of cerebral 
plaques in AD although further clarification is needed. The diagnosis and monitoring 
of AD has posed challenging and therapeutic options for the condition are limited 
therefore new concepts need to be explored. The detection of AD-associated 
pathologies in the retina has the potential to provide an answer to clinical problems; 
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